Vigabatrin: a three year clinical analysis.
The effect of introducing vigabatrin into the management of 57 patients with severe epilepsy is reported. Overall it reduced fit frequency by 50% or more in 36% of our patients. We found it to be more effective than previously reported for primary tonic-clonic seizures, but less so for complex partial seizures. Fewer of our patients withdrew from treatment due to adverse drug reactions than in earlier studies.
Martin
P J
PJ
Department of Neurology, Leicester Royal Infirmary, UK.
Millac
P A
PA
D000293:Adolescent; D000328:Adult; D000614:Aminocaproates / Q000009:adverse effects / Q000627:therapeutic use*; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D002540:Cerebral Cortex / Q000187:drug effects / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004569:Electroencephalography / Q000187:drug effects*; D004739:England; D004827:Epilepsy / Q000188:drug therapy* / Q000503:physiopathology; D004833:Epilepsy, Temporal Lobe / Q000188:drug therapy / Q000503:physiopathology; D004830:Epilepsy, Tonic-Clonic / Q000188:drug therapy / Q000503:physiopathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011358:Product Surveillance, Postmarketing; D020888:Vigabatrin
D000614:Aminocaproates; D000927:Anticonvulsants; D020888:Vigabatrin